Actelion Pharmaceuticals Ltd., a leading biopharmaceutical company headquartered in Switzerland (CH), has established itself as a pioneer in the treatment of pulmonary arterial hypertension (PAH) and other serious conditions. Founded in 1997, Actelion has achieved significant milestones, including its acquisition by Johnson & Johnson in 2017, which further solidified its market position. The company focuses on innovative therapies, particularly in the areas of cardiovascular and infectious diseases, with a portfolio that includes unique products like Tracleer and Opsumit. These therapies are distinguished by their targeted mechanisms and proven efficacy, addressing unmet medical needs. Actelion's commitment to research and development has positioned it as a key player in the biopharmaceutical industry, recognised for its contributions to improving patient outcomes globally.
We don't have data for Actelion Pharmaceuticals Ltd, but we can show you information about their parent organization instead.
View parent company